Skip to main content
Premium Trial:

Request an Annual Quote

Joint Qiagen-BD Venture Launches RNA Stabilization System

NEW YORK, April 18 – PreAnalytix, a joint venture between Qiagen and Becton, Dickinson, has launched the PaxGene Blood RNA system, a blood collection device that automatically stabilizes and purifies RNA, the companies said Wednesday. 

The system is available immediately and will be priced at $12 for a one-time-use kit for 2.5 ml of blood, said Helge Bastian, vice president of PreAnalytix and Qiagen’s Molecular Diagnostic Division. 

The system is designed to prepare RNA molecules for sample analysis, in order to enhance the accuracy of results and decrease variability. It is the first product launched by PreAnalytix.

“The concept of PreAnalytix is to provide the solution for the front end -- molecular nucleic acid base collection, stabilization, and purification,” said Bastian. In PaxGene, “the nucleic acid is made to be used, whether you do branch DNA, do arrays, or do PCR. It works for all of them.”

In the system, blood is drawn into an evacuated blood collection device, then quickly stabilized with a proprietary reagent. The system allows storage and transportation of RNA at room temperature.

PreAnalytix has garnered several customers for PaxGene, in the pharmaceutical industry and in clinical research organizations, but the customers did not want their names disclosed, said Bastian. The company hopes to make PaxGene a widely used laboratory sample preparation kit.

“We believe the PaxGene blood RNA System is a genuine enabling technology that will allow users to take an 'in vivo snapshot' of a person's gene expression pattern,” Frank Augello, a business director at BD and vice president of PreAnalytix, said in a statement.